Anthem / Blue Cross Blue Shield IVF coverage policy: step therapy, PGT-A, and what gets denied (2026)
Policy: Anthem (Elevance) Clinical UM Guideline CG-MED-103 — Assisted Reproductive Technology (Publish 2025-12-18; Last Review 2025-11-06), with CG-SURG-35 Intracytoplasmic Sperm Injection (Publish 2026-07-01; Last Review 2026-05-14) and CG-MED-88 Preimplantation Embryo Biopsy and Genetic Testing. Non-Anthem Blues (e.g., BCBS Massachusetts Policy 086, Blue Shield of California HMO Benefit Guideline 'Infertility – Additional Benefits' rev. 2026-01-01) use their own policies.. This is the clinical policy your clinic's authorization team is arguing against. Knowing it before you start avoids the most common denials.
Step therapy (IUI before IVF)
Required. Anthem CG-MED-103 requires, for IVF/ZIFT/GIFT, one of a list of qualifying conditions; for unexplained infertility and ovulatory disorders the qualifying condition is failed prior therapy: 'Failure to have a live birth after 3 cycles of IUI with oral medications for unexplained infertility' and 'For ovulatory disorders, failure to have a live birth after 6 months of conservative treatment, oral agents for 3 cycles, and 3 FSH IUIs'. Other Blues are similar but not identical — BCBS Massachusetts Policy 086 requires 6 IUI cycles before IVF for biological females under 35 and 3 IUI cycles at 35 or older unless a direct-to-IVF diagnosis is documented. Anthem's guideline has no age-based waiver of the IUI requirement; bypass is diagnosis-based only.
Bypass criteria:
- Tubal factor infertility unrelated to prior sterilization
- Pelvic adhesive disease
- 'Endometriosis Stage III or IV, following either failure to conceive after conservative surgery or when contraindications to surgery exist'
- Male factor infertility
- IVF required to support medically necessary preimplantation genetic testing (PGT-M/PGT-SR under CG-MED-88)
- BCBS MA 086 only: documented tubal factor, pelvic adhesions, endometriosis or male factor allows direct IVF without the 6/3 IUI count
- State mandate language that prohibits or limits step therapy (e.g., NY, NJ, IL, CO define cycle access by statute) — 'Federal and State mandates, as well as benefit language supersede the content of this document'
Ovarian reserve and age thresholds
- Anthem CG-MED-103: general requirement that the individual is a 'Biological female of normal reproductive age' and has 'No reversible/iatrogenic causes of infertility'
- Anthem CG-MED-103: 'For females aged 40 to <45 without documented diminished ovarian reserve: A clomiphene citrate challenge test (CCCT) should be performed annually' before a fresh IVF cycle; if ≥6 months since the prior CCCT, repeat 'basal FSH and estradiol'. Alternatives when CCCT is contraindicated: EFORT ('Inhibin B difference of < 78.6 pg/mL between Day 3 and Day 4') or combination of basal FSH, estradiol, AFC and AMH within one month
- Anthem CG-MED-103: premature ovarian insufficiency — 'Only one elevated FSH > 25 mIU/mL is required for diagnosis' (POI with autologous oocytes is not medically necessary; donor oocyte pathway applies)
- Anthem CG-MED-103: oocyte donor must be 'less than 34 years of age (as recommended by ASRM)'
- BCBS Massachusetts 086 (illustrative of stricter Blues): ages 40–41 day-3 FSH ≤15.0 mIU/mL; ages 42–43 FSH ≤12.0 mIU/mL; all ages day-3 estradiol ≤100 pg/mL; alternative 'AMH > 1.0 ng/ml, AND AFC >6'; yearly CCCT for members ≥40 and <44; coverage ends when prognosis is 'futile' (<1% live birth) or 'very poor' (1–5%)
- Blue Shield of California: no numeric ovarian reserve cutoff published; eligibility follows the SB 729 statutory definition of infertility (12 months of unprotected intercourse under 35, 6 months at 35+, or a licensed physician's findings) and the member's ART rider/EOC
Considered experimental / not medically necessary
- PGT-A: Anthem CG-MED-88 — preimplantation genetic screening for aneuploidy 'is considered not medically necessary as an adjunct to IVF, except when specified' (narrow exceptions reported: ≥3 failed prior cycles or prior aneuploid pregnancy with genetic counseling — verify current CG-MED-88 text); PGT-M/PGT-SR covered when a specific mutation or structural rearrangement is identified with documented genetic counseling
- ICSI without qualifying male factor: Anthem CG-SURG-35 covers ICSI only for 'Oligozoospermia (less than 15 million/ml)', 'Asthenozoospermia (less than 40% moving sperm)', 'Teratozoospermia (normal morphology in 4% or fewer observed sperm)' on at least two semen analyses, prior cycle with ≥50% unfertilized oocytes, anti-sperm antibodies, surgically retrieved/electroejaculated or cancer-cryopreserved sperm, PGT support, or cryopreserved oocytes; ICSI for unexplained infertility, tubal occlusion, advanced maternal age alone, low oocyte yield or routine IVF is not medically necessary, and 'More than three cycles of ICSI per attempted pregnancy is considered not medically necessary'
- Anthem CG-MED-103 'Not Medically Necessary' list: assisted embryo hatching; co-culture of embryos; direct intraperitoneal insemination (DIPI); embryo toxic factor test (ETFL); genetic engineering; human zona binding assay (hemizona); in vitro maturation of oocytes; IVF for gender selection; mock transfer; ovulation kits; PESA; peritoneal ovum and sperm transfer (POST); post-coital testing; reciprocal IVF; serum anti-sperm antibody testing; sperm acrosome reaction test; TESA (TESE/mTESE handled separately); use of donor sperm/eggs with known genetic defects
- Endometrial receptivity analysis (ERA): not addressed in CG-MED-103; Anthem LAB.00045 'Selected Tests for the Evaluation and Management of Infertility' governs infertility lab tests and treats ERA and sperm DNA fragmentation as investigational/not medically necessary (title confirmed; text not re-verified on 2026-09-06)
- BCBS Massachusetts 086 adds: sperm DNA fragmentation assays; advanced sperm selection (PICSI, Zeta potential, X/Y sorting); natural killer cell assay; endometrial scratching; EmbryoGlue; in vitro maturation; assisted hatching unless prior pregnancy with hatching or ≥3 failed implantations
Prior authorization required for
- IVF / ART cycles (Anthem: precertification per cycle under CG-MED-103; BCBS MA: 'generally required for infertility treatment except IUI', per subscriber certificate)
- Frozen embryo transfer cycles (S4037 / 58974)
- ICSI (CG-SURG-35 criteria; max 3 ICSI cycles per attempted pregnancy)
- Preimplantation genetic testing biopsy and lab (CG-MED-88; Carelon genetic testing review where delegated)
- Donor oocyte cycles (donor age <34; donor fees usually excluded)
- Surgical sperm retrieval (TESE/MESA)
- Annual CCCT / ovarian reserve documentation for ages 40–44 before each fresh cycle
- Fertility medications via the plan's specialty pharmacy (CarelonRx for Anthem)
Billing quirks that cause denials
- Blues reimburse ART largely on HCPCS S-codes: Anthem CG-MED-103 lists S4011 ('In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization...'), S4013–S4016 (GIFT, ZIFT, complete IVF case rate, frozen cycle), S4028 (MESA), S4035 (stimulated IUI case rate), S4037 (cryopreserved embryo transfer case rate) alongside CPT 58970, 58974, 89250, 89280/89281. Because S4011 already describes fertilization and embryo culture, a claim that bills S4011 plus 89250/89272 (culture) or 89280 (ICSI) is edited as duplicate; conversely, when the plan wants component CPT billing, culture (89250) and ICSI (89280/89281) are expected on the same claim/date-of-service as the retrieval (58970) and deny as 'unrelated to a covered procedure' if billed alone on a later date. Confirm the Blue's preferred structure before the cycle.
- BCBS Massachusetts 086: culture codes (89250, 89253) and oocyte identification (89254) 'may be billed once per cycle'; S4028 MESA 'payable only for congenital absence or congenital obstruction of the vas deferens'.
- ICSI is authorized separately from the IVF cycle under CG-SURG-35 and is limited to three ICSI cycles per attempted pregnancy; retrieval-day ICSI added because of an unexpected poor sample needs a same-day or retrospective authorization with the processed semen analysis (BCBS MA explicitly allows retrospective ICSI authorization when the post-processing analysis meets criteria).
- PGT biopsy (89290/89291) and lab codes are adjudicated under CG-MED-88 (Anthem) or the Blue's genetic-testing policy, often through a genetic-testing vendor (Carelon for Anthem), not under the ART authorization; PGT-A lines deny even when the IVF cycle is approved.
- Blue Card / host-plan issue: a member of one Blue treated in another Blue's service area has claims priced by the host plan but medical policy applied by the home plan; the clinic must obtain authorization from the member's home Blue, and denials cite the home plan's policy.
- Anthem's coding table is 'for informational purposes' — 'Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy' — so a listed code is not evidence the benefit exists; 'Some plans may exclude or limit coverage of infertility treatment and other associated services.'
- Blue Shield of California: IVF is excluded from the small-group 'Base ART Benefit Rider' and included only in the 'Additional ART Benefit Rider' or the SB 729 large-group base benefit; providers 'MUST confirm with Blue Shield that the member's health plan coverage is still in effect' within 5 days before the date of service.
Appeal tips
- IUI-step-therapy denial: if the diagnosis is tubal factor (not from prior sterilization), pelvic adhesive disease, stage III–IV endometriosis after surgery or with surgical contraindication, or male factor, cite the exact CG-MED-103 condition list — these qualify for IVF with no IUI count — and attach the HSG/laparoscopy report or two abnormal semen analyses. If the state has an infertility mandate (NY, NJ, IL, CO, MD, etc.), quote the statute; Anthem's own guideline states 'Federal and State mandates, as well as benefit language supersede the content of this document.'
- ICSI denial: CG-SURG-35 thresholds are numeric — '<15 million/ml', '<40% moving sperm', '≤4% normal morphology' on two analyses, or '≥50% unfertilized oocytes' in a prior cycle. Submit both semen analyses (or the prior cycle's fertilization report) and request retrospective authorization if ICSI was added on retrieval day; do not argue medical judgment alone, match the number to the criterion.
- PGT-A denial: CG-MED-88 says aneuploidy screening 'is considered not medically necessary as an adjunct to IVF, except when specified'. Check whether the member fits a stated exception (recurrent failed cycles or prior aneuploid pregnancy with genetic counseling); otherwise file external review under state law or ERISA, or convert to a covered PGT-M/PGT-SR request if a known mutation or translocation exists.
- Ages 40–44 denied for missing ovarian reserve documentation: the guideline requires an annual CCCT (or EFORT / FSH+E2+AFC+AMH within one month) before a fresh cycle; supplying the test result usually resolves the denial without a formal appeal. For non-Anthem Blues, ask the plan which numeric FSH/AMH cutoff it applied (e.g., BCBS MA's FSH ≤15 at 40–41, ≤12 at 42–43) and challenge any application of a threshold not in the written policy.
- Always identify the member's home Blue (the plan on the ID card, not the local Blue that priced the claim) and request that Blue's specific ART policy number and effective date in writing; Blues differ materially and denial letters frequently cite the wrong plan's policy.